Brief: GenSight Biologics Publishes 5 Years’ Data On LUMEVOQ®

Gensight Biologics SA

20/07/2022 06:41

July 20 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS REPORTS 5 YEARS’ DATA SHOWING SUSTAINED
EFFICACY AND SAFETY FOLLOWING ONE-TIME TREATMENT WITH LUMEVOQ®
    * COMPARED TO TREND IN VISION OBSERVED AMONG UNTREATED
PATIENTS,
FINDINGS ARE A SIGNIFICANT DIVERGENCE FROM NATURAL OUTCOMES OF
LHON
    * REVIEW OF EUROPEAN MARKETING AUTHORISATION APPLICATION FOR
LUMEVOQ® IS ONGOING, WITH DECISION FROM CHMP EXPECTED IN Q3 2023
AS A RESULT OF AN EXTENSION GRANTED BY EMA FOR GENSIGHT'S
RESPONSES TO ITS DAY 120 QUESTIONS
    * COMMERCIAL LAUNCH WILL FOLLOW APPROVAL BY END OF 2023

Source text for Eikon:  ID:nBw3rYkLCa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))